Akari Therapeutics (AKTX) Intangibles (2014 - 2026)

Akari Therapeutics has disclosed Intangibles across 13 years of filings, most recently posting $30.3 million for Q1 2026.

• Intangibles for Q1 2026 came in at $30.3 million, down 22.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.3 million (down 22.66% YoY), and the FY2025 annual result was $34.0 million, down 13.22% from the prior year.
• Intangibles came in at $30.3 million for Q1 2026 at Akari Therapeutics, down from $34.0 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $39.2 million in Q4 2024 to a low of $14000.0 in Q4 2023.
• The 5-year median for Intangibles is $34.0 million (2025), against an average of $27.0 million.
• Across the five-year window, Intangibles retreated 25.86% in 2022 and jumped 279757.14% in 2024, its largest moves.
• Akari Therapeutics' Intangibles stood at $17000.0 in 2022, then declined by 17.65% to $14000.0 in 2023, then surged by 279757.14% to $39.2 million in 2024, then declined by 13.22% to $34.0 million in 2025, then decreased by 10.88% to $30.3 million in 2026.
• The last three Intangibles figures came in at $30.3 million (Q1 2026), $34.0 million (Q4 2025), and $34.0 million (Q3 2025), per Business Quant data.